Updated 2/23/26
Stryker isn’t a household name for most people, but if you’ve ever been in a hospital or operating room, there’s a good chance you’ve come across their products. From surgical robotics and implants to hospital beds and emergency care equipment, Stryker is everywhere in the healthcare system—quietly shaping the industry from behind the scenes.
Over the years, it’s grown into a massive player with a market cap now approaching $147 billion. And while it’s known more for growth and innovation than for flashy dividends, long-term investors have found a steady and dependable income stream here too.
Recent Events
Stryker has continued building on the momentum it established heading into 2025. Revenue over the trailing twelve months reached $25.1 billion, a significant jump that reflects both organic growth and the company’s consistent ability to expand in a competitive medtech landscape. Net income came in at $3.25 billion, and EPS landed at $8.40—a cleaner earnings picture than the year prior, which was clouded by a substantial goodwill impairment charge tied to the Spine business divestiture.
That divestiture to Viscogliosi Brothers, which closed in the first half of 2025, has allowed management to sharpen its focus on higher-growth segments. The streamlining of the portfolio appears to be paying dividends in the most literal sense—free cash flow reached $4.17 billion over the trailing period, giving the company ample room to invest, acquire, and continue rewarding shareholders.
In the midst of it all, management raised the dividend again—lifting the quarterly payment from $0.84 to $0.88 per share—something they’ve done without fail for decades.
Key Dividend Metrics
📈 Forward Dividend Yield: 0.89%
💵 Forward Annual Dividend: $3.52 per share
📅 Last Dividend Payment: $0.88 per share (December 31, 2025)
📊 Payout Ratio: 40.48%
📉 5-Year Average Dividend Yield: ~1.03%
🧱 Dividend Growth Streak: 30+ years
💰 Free Cash Flow: $4.17 billion
📉 Beta: 0.87
Dividend Overview
Stryker’s dividend yield won’t knock your socks off. Sitting just under 0.9%, it’s modest compared to high-yielding sectors like utilities or energy. But there’s a reason income investors still gravitate toward names like SYK: dependability.
This is the kind of dividend that doesn’t get cut. It gets raised, slowly but surely, year after year. With a payout ratio sitting just above 40%, there’s plenty of cushion. That leaves ample room for reinvestment in the business while still rewarding shareholders with a growing income stream.
Stryker isn’t trying to attract income chasers. Instead, it’s offering a steady baseline return backed by real earnings power and strong fundamentals. The current annual dividend of $3.52 per share represents a meaningful step up from the $3.20 annualized rate that was in place just two years ago, underscoring that the growth here is tangible, not theoretical.
Dividend Growth and Safety
If you’re someone who values dividend growth more than the headline yield, Stryker deserves a close look. This company has increased its dividend every single year for more than 30 years. That’s a track record few can match, and one that spans multiple recessions, healthcare policy shifts, and global disruptions.
The most recent increase—from $0.84 to $0.88 per share quarterly—marks a 4.8% raise, consistent with the mid-single-digit growth pace investors have come to expect. What makes this particularly reassuring is that the dividend is growing in lockstep with free cash flow, not ahead of it. Operating cash flow of $5.04 billion and free cash flow of $4.17 billion dwarf the company’s total annual dividend obligation, which at current share counts amounts to a small fraction of that figure.
Safety-wise, the picture is as solid as it gets. A payout ratio of 40.48% based on reported earnings leaves substantial breathing room, even if earnings were to soften. For income investors who want to sleep well at night, Stryker’s dividend checks every box.
Analyst Ratings
Analyst sentiment on Stryker remains broadly constructive heading into 2026. The stock’s ability to generate consistent revenue growth above 10% annually while expanding its free cash flow profile has kept Wall Street’s attention firmly positive. Given the company’s execution on its portfolio streamlining strategy—most notably the spine divestiture—and its continued dominance in surgical robotics and MedSurg equipment, analysts have maintained Overweight and Buy ratings across the major coverage universe.
Price targets have generally clustered in the $410 to $460 range, reflecting a consensus view that shares at $384.73 still offer upside from current levels, even after accounting for the premium valuation the market has historically assigned to Stryker. The company’s beta of 0.87 reinforces the view that this is a lower-volatility name, which tends to attract both growth-oriented and income-focused institutional buyers.
Analysts covering the medtech space broadly have pointed to Stryker’s MAKO robotic platform as a sustained competitive advantage, particularly as elective procedure volumes continue recovering and hospitals invest in next-generation surgical infrastructure. That positioning, combined with Stryker’s international expansion efforts, has kept analyst sentiment tilted decidedly to the upside. While no coverage is without nuance, the prevailing view appears to be that the company’s earnings trajectory and cash generation support a higher stock price over a 12-month horizon.
Earning Report Summary
Strong Top-Line Growth in a Challenging Environment
Stryker’s most recent full-year results reflected a materially cleaner earnings picture compared to the prior year, when a goodwill impairment charge on the Spine business weighed heavily on reported net income. Revenue for the trailing twelve-month period reached $25.1 billion, a strong step up from the $22.6 billion reported the prior year. That represents top-line growth in excess of 11%—a remarkable pace for a company already operating at significant scale in a mature industry.
Net income of $3.25 billion and EPS of $8.40 reflect genuine underlying earnings improvement, with the distortion of prior-year charges now behind the company. Profit margins, while not extraordinarily wide at 12.92%, are consistent with a medtech business that carries substantial R&D and commercial infrastructure costs.
Segment Performance: MedSurg and Ortho Carry the Load
The MedSurg and Neurotechnology segment continued to be the primary revenue engine, benefiting from strong demand across surgical equipment, endoscopy, and neurovascular product lines. Elective procedure volumes have remained elevated, giving the Orthopaedics segment a favorable backdrop as well. The MAKO robotic platform, which drives both implant pull-through and hospital capital spending, continues to gain share in the surgical robotics market.
The divestiture of the U.S. Spine business has clarified the segment reporting picture and allowed management to concentrate resources on areas where Stryker has a durable competitive advantage. The result is a leaner, more focused portfolio that generates stronger returns on invested capital.
Cash Flow Tells the Real Story
Perhaps the most compelling element of Stryker’s recent financial performance is the cash flow generation. Operating cash flow of $5.04 billion and free cash flow of $4.17 billion represent a meaningful improvement over prior periods and give the company significant optionality. That capital can fund bolt-on acquisitions, share repurchases, debt reduction, or continued dividend growth—and based on history, management has done a disciplined job allocating across all of those channels.
Return on equity of 15.08% and return on assets of 7.92% round out a financial profile that reflects operational efficiency and a well-managed balance sheet. These aren’t numbers that suggest a business straining under its own weight.
Looking Ahead
With the portfolio now streamlined and free cash flow at record levels, Stryker enters 2026 from a position of strength. Organic revenue growth in the high single digits to low double digits remains the target, and the company’s innovation pipeline—particularly in robotics and digital surgery—provides a credible path to sustaining that trajectory. For dividend investors, the more important takeaway is that the cash engine funding those raises is running better than ever.
Financial Health and Stability
Stryker’s balance sheet continues to reflect a company that generates far more cash than it needs to sustain operations. With operating cash flow north of $5 billion and free cash flow above $4.17 billion, the financial cushion available to management is substantial. The company’s return on equity of 15.08% is solid for a business that doesn’t rely on extreme leverage to produce results, and return on assets of 7.92% points to genuine operational efficiency across a broad product portfolio.
The profit margin of 12.92% is healthy in the context of a business that carries meaningful R&D commitments and a large global commercial footprint. Book value per share of $58.61 and a price-to-book ratio of 6.56 reflect the premium the market assigns to Stryker’s earnings power and brand durability—multiples that have been consistently supported by the company’s track record of execution. Across virtually every dimension of financial health, Stryker presents as a low-risk, high-quality operator.
Valuation and Stock Performance
At $384.73, Stryker is trading toward the middle of its 52-week range of $329.16 to $404.87. The stock has pulled back modestly from its 52-week high of $404.87, which may present a more attractive entry point for investors who have been waiting on the sidelines. The P/E ratio of 45.80 based on reported earnings looks elevated at first glance, but that multiple reflects both the premium quality of the business and the fact that reported earnings still carry some noise from transition costs and one-time items.
Stryker isn’t cheap, and it’s probably never going to be. That’s the price of consistency, innovation, and a dividend growth streak measured in decades rather than years. Long-term holders have found that paying a fair premium for Stryker’s earnings quality tends to be well rewarded over a full market cycle. With a beta of 0.87, the stock tends to absorb market volatility better than average—a characteristic that suits income investors who prioritize capital preservation alongside dividend growth.
Risks and Considerations
No company is risk-free, and Stryker faces a few considerations that income investors should keep in mind. Healthcare policy remains an ever-present variable. Changes in reimbursement structures, pricing pressure from hospital systems looking to reduce costs, or regulatory shifts affecting device approvals could all create headwinds for revenue and margins.
Currency exposure is another ongoing factor. Stryker generates a meaningful portion of revenue outside the United States, and a persistently strong dollar can dilute the value of international sales when translated back to reported figures. This isn’t unique to Stryker, but it bears watching in periods of dollar strength.
The company’s debt load, while manageable relative to its cash generation, is not trivial. A rising interest rate environment could modestly increase financing costs over time as existing obligations are refinanced. And while the Spine divestiture was strategically sound, any large acquisition—which Stryker has historically used as a growth lever—introduces execution risk and potential balance sheet pressure.
Finally, the P/E ratio of 45.80 leaves limited room for earnings disappointment. If organic growth were to decelerate or margins were pressured more than expected, the valuation could compress even if the underlying business remains sound. None of these are reasons to avoid the stock, but they are legitimate considerations for sizing and entry timing.
Final Thoughts
Stryker is a quiet performer in the dividend world. You won’t see it topping any yield charts, but that’s not really the point here. This is a company that grows its payout year after year—now at $3.52 annually after the most recent raise—backed by a resilient business, record free cash flow, and a management team that has proven it takes the dividend commitment seriously.
For investors focused on income stability, dividend growth, and long-term compounding, Stryker fits the profile well. The combination of a 30-plus-year growth streak, a conservative payout ratio just above 40%, and over $4 billion in annual free cash flow makes this one of the more durable dividend growers in the healthcare sector.
While it may not be the flashiest choice at current valuation levels, it has a great deal going for it beneath the surface. Sometimes, the best dividend stocks are the ones that just quietly do their job—and Stryker has been doing exactly that for a very long time.